FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev ® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILDInterstitial lung disease (ILD) is the leading cause of death among people with systemic sclerosis (SSc) or scleroderma3  Approval is based on results from the Phase III SENSCIS ® study, the largest randomized controlled trial in SSc-ILD patientsRegulatory review of the additional indication in other countries is still ongoingOfev ® (nintedanib) is already approved in the U.S. and more than 70 countries for the treatment of idiopathic pulmonary fibrosis (IPF)
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Research | Scleroderma | Study